Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered NK cell therapies for cancer, will present at the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:00 a.m. ET. The event will feature a fireside chat, and a simultaneous webcast will be accessible on Nkarta's website. A replay will be available for four weeks following the event. Nkarta is advancing off-the-shelf NK cell therapies utilizing advanced technologies to enhance anti-tumor activity and improve patient access.
Nkarta, Inc. (Nasdaq: NKTX) has appointed Dr. David R. Shook as Vice President of Clinical Development, set to lead clinical and regulatory activities. Dr. Shook, a pioneer in NK cell therapy, previously directed Nkarta’s NKX101 and NKX019 programs. Kanya Rajangam, MD, PhD, resigns as Chief Medical Officer, effective June 5, 2022. Nkarta continues progressing in its clinical trials, with NKX101 and NKX019 showing early anti-tumor activity. Updated data is expected to be presented at a medical meeting later this year.
Nkarta, Inc. (Nasdaq: NKTX) reported positive preliminary results from its NKX101 and NKX019 Phase 1 trials for treating relapsed/refractory AML and NHL. In NKX101, 60% of AML patients achieved complete responses, with MRD negativity observed in two cases. NKX019 showed a 50% complete response rate in NHL patients. Both therapies demonstrated a favorable safety profile, unlike traditional CAR T cell treatments. Following a $230 million public offering, Nkarta holds over $400 million in liquid assets, ensuring operational funding into 2025.
Nkarta, Inc. (Nasdaq: NKTX) has successfully completed a public offering of 15,333,334 shares of its common stock, raising approximately $230 million. Each share was priced at $15.00, including an additional 2,000,000 shares purchased through the underwriters’ full exercise of their option. The funds will support the continued clinical development of NKX101 and NKX019, preclinical studies, and the expansion of manufacturing capabilities. The offering was conducted under a SEC shelf registration statement effective since September 2, 2021.
Nkarta, Inc. (Nasdaq: NKTX) announced an underwritten public offering of 13,333,334 shares at $15.00 per share, aiming to raise approximately $200 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to 2,000,000 additional shares. Proceeds will support the clinical development of NKX101 and NKX019, preclinical studies, and enhance manufacturing capabilities. The offering is set to close around April 28, 2022, pending standard conditions. Cowen, SVB Securities, Evercore ISI, and Stifel serve as joint book-running managers.
Nkarta, Inc. (Nasdaq: NKTX) announced a proposed underwritten public offering to issue and sell $150 million of common stock, with an option for underwriters to purchase an additional $22.5 million. The offering is subject to market conditions, with no guarantee of completion. Proceeds will fund clinical development of NKX101 and NKX019, preclinical studies, internal manufacturing capabilities, and general corporate purposes. The offering follows SEC guidelines and will be conducted through a shelf registration statement.
Nkarta, Inc. (Nasdaq: NKTX) reported positive Phase 1 results for its CAR NK cell therapies, NKX101 and NKX019, focusing on hematologic malignancies. In NKX101, 60% of patients with relapsed/refractory AML achieved complete responses, with 2 being MRD negative. NKX019 demonstrated an 83% overall response rate in relapsed/refractory NHL, with a 50% complete response rate. Both therapies exhibited a favorable safety profile, with no severe toxicities reported. Nkarta continues to evaluate higher doses in ongoing clinical trials, with further data expected at future medical meetings.
SOUTH SAN FRANCISCO, Calif., April 22, 2022 – Nkarta, Inc. (Nasdaq: NKTX) will hold a conference call on April 25, 2022, at 8:00 a.m. ET to discuss clinical data from ongoing Phase 1 trials for its lead programs, NKX101 and NKX019. Leading investigators will join management for the update. NKX101 targets NKG2D ligands in patients with acute myeloid leukemia and myelodysplastic syndromes, while NKX019 targets CD19 in B cell malignancies. The results will provide insights into the safety and anti-tumor activity of these investigational therapies.
Nkarta, Inc. (Nasdaq: NKTX) presented four preclinical data abstracts at the AACR Annual Meeting 2022, showcasing advancements in its engineered NK cell therapies for cancer treatment. Key highlights included findings on multiplexed gene knockout strategies that enhance the efficacy of CD70 CAR NK cells, particularly in combating renal cell carcinoma. The company continues to expand its NK cell platform and pipeline, including its NK+T cell program, indicating a robust commitment to innovative cancer therapies.
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer cell therapies for cancer, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET. A webcast of the presentation will be available in the Investors section of Nkarta’s website and can be accessed after the live event for approximately four weeks. Nkarta specializes in developing off-the-shelf NK cell therapies designed for outpatient treatments, leveraging advanced cell engineering and cryopreservation technologies.